Global Hemostats Market valued at $2.7 billion in 2021, is set to witness a decent growth of 6% by 2026

Hemostasis is the body’s natural reaction to an injury that stops bleeding and repairs the damage. The capability helps in conserving blood and prevents infection. Hemostats are surgical tools that are used in surgical procedures to control bleeding.

Technological Advancements are driving the Hemostats Market Growth

Uncontrollable bleeding poses substantial fatality risks and costs in the battlefield, emergency, and hospital settings. To address these concerns, players operating in the market are focusing on developing hemostatic agents that can rapidly control bleeding, possess antibacterial properties, can be used as adjuncts to control bleeding during surgical procedures, and control residual problematic bleeding if conventional methods fail.

• In Feb 2022, Futura Surgicare Pvt Ltd.’s new vertical Dolphin Hemostats launched hemostatic products under the brand Hemostax (Oxidised Regenerated Cellulose). Hemostax Standard is an absorbable hemostat that is designed to help surgeons control bleeding more efficiently.
• In July, 2021, Medcura, Inc. launched a new class of high-performance, antibacterial hemostatic gel, Rapid-Seal®. It provides rapid bleeding management and antibacterial capabilities to improve wound treatment, help fight infections of the wound and promote an environment for safe healing.

Plastic Surgery - An Untapped Market

Plastic surgery represents a commercially lucrative opportunity for the hemostats market. Similar to most surgical procedures, plastic surgery procedures are also not without associated complications. Seromas and hematomas are relatively common complications associated with plastic surgery procedures. These complications adversely impact wound healing and result in substantial morbidity in patients. The use of hemostatic agents can significantly reduce these complications, achieve immediate hemostasis for the local bleeding site, allow earlier drain removal, and potentially avoid the use of drains altogether.

“Technologically advanced products are likely to be successful in the market. I think, there is only one product in the market that has complementary characteristics of advanced bleeding control and antimicrobial activity.” - Director, Leading Hemostat Manufacturer, United States

Emerging Markets Set to Drive the Hemostatic Agents Market

Emerging markets such as China, India, and South Korea are expected to witness double-digit growth in the upcoming years. The growth in the emerging markets is likely to be driven by lower-priced hemostatic products that are largely commoditized. The huge volume of surgical procedures, rising cases of trauma injuries, increasing cases of organ transplantation (legal & illegal), foray of local market players, and growing capabilities of surgeons to undertake more complex and technically-challenging procedures that require efficacious, fast-acting hemostats to control bleeding are some of the key factors that are expected to fuel the demand of hemostatic agents in emerging markets.

Competitive Landscape Analysis: Global Hemostats Market

The global hemostats market is marked by the presence of top market players such as Baxter, Ethicon, B. Braun, Becton Dickinson, Pfizer, CryoLife, Teleflex (Z-Medica), Integra LifeSciences, Biomup, Medtronic, etc.

Get Customized Research Report on Hemostats Market @ https://meditechinsights.com/hemostats-market/